Overview
The purpose of this study is to evaluate the concentration of afamelanotide in serum after the administration of afamelanotide in adolescent and adult EPP patients.
Eligibility
Inclusion Criteria:
- EPP patients aged between 12 and 70 years
- BMI between 15 and 30 kg/m2
- >50 kg
Exclusion Criteria:
- Any personal or direct family history of melanoma
- Any significant history of allergy and/or sensitivity to any of the contents of study drug product or lignocaine or other local anaesthetics if used
- Any significant illness during the four weeks before the study screening period
- Any evidence of hepatic or renal impairment
